2024
1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials
BJORNSTAD P, DANNE T, TAMBORLANE W, KLINGENSMITH G, SCHUELER E, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S, LAFFEL L. 1140-P: Impact of Empagliflozin on Hyperfiltration in Youth with Type 2 Diabetes—Post Hoc Analysis of the DINAMO and DINAMO MONO Trials. Diabetes 2024, 73 DOI: 10.2337/db24-1140-p.Peer-Reviewed Original ResearchDiabetic kidney diseaseKidney diseaseHoc analysisDiabetic kidney disease riskEarly diabetic kidney diseaseBaseline to weekImpact of empagliflozinCystatin C equationClinically relevant improvementNational Institute of DiabetesDigestive and Kidney DiseasesPost hoc analysisEGFR changeIncreased riskHyperfiltrationPubertal statusGlycemic controlEGFRC equationLong-term effectsPotential long-term effectsRelevant improvementNormofiltrationT2DHealthy youth
2023
1162-P: Promoting Career Development of Physicians Engaged in Type 1 Diabetes (T1D) Research—The New DiabDocs Multicenter National K12 Program
DASANI K, BISHOP F, GOLDEN S, LAFFEL L, MIRMIRA R, STECK A, TAMBORLANE W, WILLI S, MAAHS D, DIMEGLIO L. 1162-P: Promoting Career Development of Physicians Engaged in Type 1 Diabetes (T1D) Research—The New DiabDocs Multicenter National K12 Program. Diabetes 2023, 72 DOI: 10.2337/db23-1162-p.Peer-Reviewed Original ResearchK12 programEffects of mentoringProductive academic careerPromote career developmentLetter of intentMentoring communityAcademic careerCareer trajectoriesCareer developmentProgram administratorsPhysician-scientistsRate of physiciansDiversity trainingProgram trainingLeadership CommitteeTraining experienceScientific Review CommitteeDigestive and Kidney DiseasesResearch supportInstitutionsCareerDiabetes InstituteNationwide cohortProgramAdvisory Panel164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo
LAFFEL L, DANNE T, TAMBORLANE W, KLINGENSMITH G, NEUBACHER D, TARTAKOVSKY I, MARQUARD J, ZEITLER P, WILLI S. 164-LB: Durable Improvement in HbA1c in Youth-Onset T2D—A Post Hoc Analysis of the DINAMO Trial of Empagliflozin and Linagliptin vs. Placebo. Diabetes 2023, 72 DOI: 10.2337/db23-164-lb.Peer-Reviewed Original ResearchHbA1c <Increasing prevalence of childhood overweightGlycemic controlPrevalence of childhood overweightSafety of empagliflozinLinagliptin 5 mgClinically meaningful responseYouth-onset T2DOnset of complicationsBeta-cell functionPost hoc analysisEmpagliflozin groupClinical courseFPG levelsChildhood overweightSGLT2 inhibitorsEmpagliflozinYouth-onsetPlaceboHbA1c changeMeaningful responseHbA1cHigher HbA1cHoc analysisIncreased prevalence
2022
DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice
Doyle EA, Weinzimer SA, Tamborlane W. DKA Prevention and Insulin Pumps: Lessons Learned From a Large Pediatric Pump Practice. The Science Of Diabetes Self-Management And Care 2022, 48: 476-482. PMID: 36129121, DOI: 10.1177/26350106221125699.Peer-Reviewed Original ResearchConceptsContinuous glucose monitorHigher A1C levelsA1c levelsDKA eventsInsulin pumpPump usersPump-treated patientsRetrospective chart reviewPediatric endocrinology practiceType 1 diabetesInsulin pump usersConcurrent illnessDKA preventionPump patientsDiabetes durationDKA episodesMean A1CChart reviewEndocrinology practiceDKA ratesDKA severityMean ageInsulin omissionMost episodesPatientsCommentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection
Gujral J, Tamborlane W, Nally L. Commentary on CDC data showing an increased risk for pediatric diabetes with COVID‐19 infection. Journal Of Diabetes 2022, 14: 630-632. PMID: 36073304, PMCID: PMC9512767, DOI: 10.1111/1753-0407.13311.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionIncidence of diabetesBody mass indexType of diabetesMortality Weekly ReportCommercial health insurancePrevention's MorbidityMass indexPediatric diabetesViral variantsSocial determinantsDisease controlDiabetesRecent CentersHealth insuranceCDC dataSignificant increaseInfectionWeekly reportsMorbidityIncidenceA Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes
Reiss AL, Jo B, Arbelaez AM, Tsalikian E, Buckingham B, Weinzimer SA, Fox LA, Cato A, White NH, Tansey M, Aye T, Tamborlane W, Englert K, Lum J, Mazaika P, Foland-Ross L, Marzelli M, Mauras N. A Pilot randomized trial to examine effects of a hybrid closed-loop insulin delivery system on neurodevelopmental and cognitive outcomes in adolescents with type 1 diabetes. Nature Communications 2022, 13: 4940. PMID: 36042217, PMCID: PMC9427757, DOI: 10.1038/s41467-022-32289-x.Peer-Reviewed Original ResearchConceptsHybrid closed-loop insulin delivery systemStandard care groupType 1 diabetesClosed-loop insulin delivery systemWhite matter volumeCare groupPrimary outcomeInsulin delivery systemsMatter volumeFractional anisotropyCognitive AssessmentRigorous glucose controlDiagnosis of T1DClosed-loop groupBetter diabetes controlDiabetes care groupsConcept pilot studyYears of ageAcademic medical centerFunctional brain activityCortical surface areaMonths study durationRandomized participantsDiabetes controlGlucose controlAmerican Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022, 28: 923-1049. PMID: 35963508, PMCID: PMC10200071, DOI: 10.1016/j.eprac.2022.08.002.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesEvidence-based recommendationsPractice guidelinesGlycemic targetsDiabetes mellitusComprehensive careCare plansEvidence-based clinical practice recommendationsEndocrinology Clinical Practice GuidelineNew evidence-based recommendationsLiterature searchManagement of prediabetesDiabetes care teamDiabetic kidney diseaseClinical practice recommendationsComprehensive care planType 1 diabetesAmerican AssociationCare of personsHealth care professionalsSecondary diabetesBariatric surgeryInsulin therapyClinical evidenceKidney diseaseOnce-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaselineThe obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study
Levitsky LL, Drews KL, Haymond M, Glubitosi-Klug RA, Katz L, Mititelu M, Tamborlane W, Tryggestad JB, Weinstock RS, Group T. The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study. Journal Of Diabetes And Its Complications 2022, 36: 108259. PMID: 36150365, DOI: 10.1016/j.jdiacomp.2022.108259.Peer-Reviewed Original ResearchConceptsNon-proliferative diabetic retinopathyType 2 diabetesHigh-sensitivity C-reactive proteinObesity paradoxInflammatory biomarkersHDL cholesterolLDL cholesterolInsulin-like growth factor binding protein 1Sensitivity C-reactive proteinGrowth factor binding protein 1Today StudyPresence of retinopathyRelationship of obesityC-reactive proteinPlasminogen activator inhibitor-1Tumor necrosis factor receptor 1Digital fundus photographsNecrosis factor receptor 1Activator inhibitor-1Factor receptor 1Higher BMIObese participantsRisk markersDiabetic retinopathyInterleukin-6SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. Pediatrics 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretionEfficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnelLong-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study
Van Name MA, Kanapka LG, DiMeglio LA, Miller KM, Albanese-O’Neill A, Commissariat P, Corathers SD, Harrington KR, Hilliard ME, Anderson BJ, Kelley JC, Laffel LM, MacLeish SA, Nathan BM, Tamborlane WV, Wadwa RP, Willi SM, Williams KM, Wintergerst KA, Woerner S, Wong JC, DeSalvo DJ. Long-term Continuous Glucose Monitor Use in Very Young Children With Type 1 Diabetes: One-Year Results From the SENCE Study. Journal Of Diabetes Science And Technology 2022, 17: 976-987. PMID: 35343269, PMCID: PMC10348002, DOI: 10.1177/19322968221084667.Peer-Reviewed Original ResearchConceptsFamily behavioral interventionsContinuous glucose monitoringBlood glucose monitoringCGM useYoung childrenGlucose monitoringOne-year resultsType 1 diabetesContinuous glucose monitor useHemoglobin A1cCGM groupGlycemic outcomesType 1Behavioral interventionsExtension phaseBGM groupMonitor useOne-year studyCGM technologyDiabetes technologyGlycemiaHypoglycemiaChildrenBehavioural supportGroupYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetesContinuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.
Gubitosi-Klug RA, Braffett BH, Bebu I, Johnson ML, Farrell K, Kenny D, Trapani VR, Meadema-Mayer L, Soliman EZ, Pop-Busui R, Lachin JM, Bergenstal RM, Tamborlane WV. Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study. Diabetes Care 2022, 45: 659-665. PMID: 35076697, PMCID: PMC8918229, DOI: 10.2337/dc21-0629.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringInsulin pumpDCCT/EDIC studyComplications Trial/EpidemiologyGlucose monitoringPercent timeRelevant clinical goalsYears of ageMean sensor glucoseSubset of adultsComplications StudyEDIC studyEntire recording periodOlder patientsGlycemic excursionsDiabetes controlSignificant hypoglycemiaDiabetes InterventionsYears durationHypoglycemiaSensor glucoseClinical goalsHyperglycemic excursionsType 1Tobacco use patterns and clinical outcomes in the T1D exchange
Rash CJ, Alessi SM, Foster N, Tamborlane W, Van Name MA, Wagner JA. Tobacco use patterns and clinical outcomes in the T1D exchange. Journal Of Diabetes And Its Complications 2022, 36: 108128. PMID: 35058139, PMCID: PMC8881793, DOI: 10.1016/j.jdiacomp.2022.108128.Peer-Reviewed Original ResearchConceptsFormer usersTobacco useDiabetic ketoacidosis episodesTobacco cessation interventionsT1D Exchange RegistryCurrent tobacco useTobacco use patternsTobacco use statusCurrent usersSelf-reported outcomesBlood glucose monitoring frequencyCross-sectional comparisonDaily useTobacco statusClinical outcomesKetoacidosis episodesT1D ExchangeCessation interventionsBlood glucoseWorse outcomesDiabetes indicatorsNeuropathy diagnosisStandardized questionnaireMost outcomesDeleterious association
2021
Late Endocrine Effects after Stem Cell Transplant in a Young Girl with Griscelli Syndrome
Mencher SR, Tamborlane WV, Patel AD. Late Endocrine Effects after Stem Cell Transplant in a Young Girl with Griscelli Syndrome. Case Reports In Pediatrics 2021, 2021: 9981306. PMID: 34987878, PMCID: PMC8723881, DOI: 10.1155/2021/9981306.Peer-Reviewed Original ResearchStem cell transplantAnti-Mullerian hormoneGrowth failureGriscelli syndromeCell transplantOvarian failureLate endocrine effectsPersistent growth failureLow ovarian reservePremature ovarian failurePoor weight gainInitial biochemical evaluationSevere short statureEosinophilic enterocolitisGlucocorticoid useHost diseaseUnderlying illnessOvarian reserveAutoimmune conditionsGH therapyGraves' diseasePremature menopauseInflammatory conditionsSevere immunodeficiencyHypergonadotropic hypogonadismWithdrawn as duplicate: Corrigendum to: Continuous Glucose Monitoring: An Endocrine Society Clinical Practice Guideline
Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H. Withdrawn as duplicate: Corrigendum to: Continuous Glucose Monitoring: An Endocrine Society Clinical Practice Guideline. The Journal Of Clinical Endocrinology & Metabolism 2021, 107: e2220-e2220. PMID: 34878114, DOI: 10.1210/clinem/dgab251.Peer-Reviewed Original ResearchCase Report: Managing Pregnancy With Type 1 Diabetes Using a Do-It-Yourself Artificial Pancreas System.
Waikar AR, Arora T, Haynes M, Tamborlane WV, Nally LM. Case Report: Managing Pregnancy With Type 1 Diabetes Using a Do-It-Yourself Artificial Pancreas System. Clinical Diabetes 2021, 39: 441-444. PMID: 34866788, PMCID: PMC8603326, DOI: 10.2337/cd20-0128.Peer-Reviewed Original ResearchRacial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC).
Bacha F, Cheng P, Gal RL, Beaulieu LC, Kollman C, Adolph A, Shoemaker AH, Wolf R, Klingensmith GJ, Tamborlane WV. Racial and Ethnic Disparities in Comorbidities in Youth With Type 2 Diabetes in the Pediatric Diabetes Consortium (PDC). Diabetes Care 2021, 44: 2245-2251. PMID: 34475033, DOI: 10.2337/dc21-0143.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesNon-Hispanic blacksPediatric Diabetes ConsortiumFatty liver diseaseWorse metabolic controlRacial-ethnic disparitiesNon-Hispanic white youthManagement of youthSubsequent comorbiditiesDiabetic ketoacidosisInitial presentationLiver diseaseMean ageRegistry participantsMedical recordsC-peptideClinical dataDiabetesMetabolic controlHealth outcomesRacial-ethnic differencesEthnic disparitiesComorbiditiesRacial-ethnic groupsAssociations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes.
Gubitosi-Klug R, Gao X, Pop-Busui R, de Boer IH, White N, Aiello LP, Miller R, Palmer J, Tamborlane W, Wallia A, Kosiborod M, Lachin JM, Bebu I. Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes. Diabetes Care 2021, 44: 1499-1505. PMID: 33980605, PMCID: PMC8323173, DOI: 10.2337/dc20-3104.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAlbumin excretion rateNonfatal myocardial infarctionSubsequent cardiovascular diseaseCardiovascular diseaseMicrovascular complicationsMyocardial infarctionMicrovascular diseaseSubsequent riskDCCT/EDIC cohortTraditional CVD risk factorsUrinary albumin excretion rateAdvanced microvascular diseaseSubclinical myocardial infarctionAdverse cardiovascular eventsCoronary artery revascularizationCVD risk factorsGlomerular filtration rateSignificant macular edemaType 1 diabetesProportional hazards modelRetinal fundus photographyArtery revascularizationComplications StudyNonfatal stroke